GILD: Gilead Sciences, Inc. - Summary | Jitta

Gilead Sciences, Inc.

NASDAQ:GILD

Price
$78.21
Loss Chance
45.1%
5.23JITTA SCORE
27.27%Over Jitta Line
Jitta Ranking
99 / 852
1,558 / 4,159
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (10)
Recent Business Performance (55)
Financial Strength (70)
Return to Shareholders (95)
Competitive Advantage (60)
Jitta Signs
Return on EquityConsistently High
Dividend PayoutIncreasing Every Year
Share RepurchaseEvery Year
CapExVery Low
Revenue and EarningRevenue decline from 2016-2019
Operating MarginDeclined
Recent Business PerformanceEarning decline 14.62% in the last year
Key Stats
Jitta Score
Jitta Line
5.23
27.27%
1.57
132.87%
2.47
423.91%
Biotechnology
7.28
47.30%
7.13
52.19%
5.26
23.09%
COMPANY DESCRIPTION
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; and Zydelig, a kinase inhibitor for the treatment of patients with relapsed chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma. In addition, the company offers Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. Further, it provides its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Additionally, the company focuses to develop product for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. It markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with The Rockefeller University; Novartis AG; Lyndra Therapeutics, Inc.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Eisai Co., Ltd.; Galapagos NV; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; and Kiniksa Pharmaceuticals, Ltd. The company was founded in 1987 and is headquartered in Foster City, California.